Supreme Court refuses to hear pharma challenges to Medicare price negotiation program

The U.S. Supreme Court declined to review lawsuits filed by several brand‑name drug makers against the Medicare drug price negotiation program, dealing a significant setback to the industry.

The companies that sought judicial relief included AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Novartis and Novo Nordisk. Their cases will now remain unresolved in lower courts.

Separately, Maryland's Prescription Drug Affordability Board announced it will set an upper payment limit for the diabetes drug Ozempic, aiming to curb costs for state residents.

The combined developments highlight growing regulatory pressure on pharmaceutical pricing and could influence future market dynamics.